Page 9 - Confidence Interval News Today

Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs. sunitinib at eight years from the...

Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator?s choice of chemotherapy as a first-line treatment for patients...

First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to...

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

1. In this randomized controlled trial, for patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease (IAD), a drug-eluting resorbable scaffold was superior to angioplasty in reducing the risk of vascular events. 2. There was no significant difference in the adverse events between the drug-eluting resorbable scaffold and angioplasty groups. Evidence Rating Level:

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description In this episode, we begin by discussing our article of the week which comes from

1. In this randomized controlled trial, doxycycline post-exposure prophylaxis (PEP) did not significantly reduce the risk of bacterial sexually transmitted infections (STIs) compared to standard care. 2. Doxycycline testing using hair indicated low protocol adherence by study participants. Evidence Rating Level: 1 (Excellent) Study Rundown: The incidence of bacterial STIs is increasing worldwide, prompting investigation

1. In this randomized-controlled trial, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide reduced the risk of cardiovascular death, myocardial infarction, and stroke in obese patients without diabetes. 2. Semaglutide was associated with a higher risk of adverse events resulting in discontinuation compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is an emerging

1. In this randomized controlled trial, percutaneous coronary intervention (PCI) resulted in decreased symptoms compared to a placebo procedure in patients with stable angina. 2. The incidence of serious adverse events was comparable for both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Angina is often one of the first discernible symptoms of underlying coronary

1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The mainstay of T1DM treatment is